CRISPR: From Bacterial Defense System to Tool of the Future


When a bacterium was smarter than a scientist

Just after breakfast, sitting in his laboratory at the University of Alicante, Francisco Mojica stared at his computer screen in dismay. It was the 1990s, and he had just created a database of DNA sequences of extreme bacteria—organisms that lived in conditions that would kill almost any other life. These bacteria inhabited salt-saturated lakes—organisms adapted to be “salt lovers,” as their scientific name, halobalilia, implied.labiotech+1

But instead of the usual, orderly DNA sequences he expected, Mojica stumbled upon something strange: regularly repeated DNA fragments, separated by spaces with ever-changing sequences . They were like repeated words in a strange verse—”word-space-word-space-word.” Interesting. Almost like an archive. But an archive of what?wikipedia

Little did he know that he had just discovered one of the most groundbreaking technologies that would fundamentally revolutionize medicine, agriculture, and biology over the next two decades.

First Spark: The Strange Sequence from 1987

The history of CRISPR (acronym for Clustered Regularly Interspaced Short Palindromic Repeats) begins earlier, in Japan.bitesizebio

In 1987, while working on the gene encoding alkaline phosphatase in E. coli , Japanese scientist Yoshizumi Ishino and his team had an unexpected surprise. While cloning DNA for an experiment, they stumbled upon fragments of DNA that were repeated—a highly unusual finding. These sequences were organized into clusters and were regularly distributed along the bacterial genome.biocompare+1

Ishino and his team published their observations, but their significance was never fully explored. This discovery languished in the scientific literature, like a hidden treasure waiting for adventurers.biocompare

The Key to the Puzzle: Francisco Mojica Discovers the Function

Flash forward to the year 2000. Francisco Mojica, now a researcher at the University of Alicante, was working on a different question: how do bacteria from extreme environments adapt to changes in salt concentration? But his curiosity quickly veered elsewhere.labiotech

Using access to growing genetic databases, he began comparing these strange, repetitive sequences Ishino had previously discovered. Imagine his surprise when he discovered that the same repeats appeared in the genomes of bacteria studied around the world—in microorganisms from the ocean, soil, and caves .biocompare

In 2000, he and his colleagues published work showing that this cluster was highly evolutionarily conserved—and therefore must have meant something important. Its very preservation over millions of years of evolution indicated that nature does nothing without reason.biocompare

But that was just the beginning.

Eureka Moment: Virus in Bacterial DNA

A few years later, while comparing databases, Mojica noticed something extraordinary: DNA fragments nested between repeats in the bacterial genome were identical to fragments of the genomes of viruses (bacteriophages) that attack bacteria .labiotech

Not just any fragments – but fragments of actual viruses infectious to those same bacteria!

It was an immediately logical presumption: if a bacterium stores fragments of a virus’s DNA in its cell, it must have acquired this genetic material somehow . And if it holds them, it must need them for something.labiotech

Mojica hypothesized: CRISPR is a bacteria’s adaptive immune system . Once a virus attacks a bacterium and it becomes infected, part of the virus’s genome is squeezed into the CRISPR archive. The next time the same virus tries to attack that bacterium (or its descendants), the immune system will “remember” it and attack it.wikipedia+1

Sounds almost like memory? Because that’s exactly what it is— biological, genetic memory .

A path through the groves of scientific journals

In 2003, Mojica wrote a paper proposing this theory. He submitted it to Nature , one of the world’s most prestigious scientific journals. It was rejected. He tried the Proceedings of the National Academy of Sciences . It was rejected.wikipedia

Then Molecular Microbiology . Refusal.wikipedia

Nucleic Acids Research . Once again – refusal.wikipedia

He was frustrated, but he didn’t give up. The paper finally made it to the Journal of Molecular Evolution in February 2005. It wasn’t Nature, but it was a publication. Importantly, that same year, independently of Mojica’s work, another laboratory published similar findings.flagshippioneering+1

But something changed. Scientists began to listen.

Experimental Proof: Horvath and Siksnys Show It Works

Although Mojica proposed the hypothesis, experimental evidence came from a completely different direction – from laboratories that were studying… ferments for yogurt production.pmc.ncbi.nlm.nih

In 2005, Philippe Horvath’s team at Danisco (yes, the dairy giant!) investigated how Streptococcus thermophilus bacteria – used to produce yogurt and cheese – could be resistant to infectious viruses (bacteriophages).pmc.ncbi.nlm.nih

Horvath and his colleagues demonstrated experimentally what Mojica had proposed theoretically: when S. thermophilus was infected with a new bacteriophage, the bacterium integrated new sequences derived from the phage’s genome directly into its CRISPR region of DNA . Even better, the next time the same phage tried to infect descendants of that bacterium, they were resistant.pmc.ncbi.nlm.nih

This was not just a theory – it was experimental proof of a working biological immune system.pmc.ncbi.nlm.nih

Separately, that same year, Vytautas Siksnys from Lithuania published a paper showing that the CRISPR system from one bacterium ( S. thermophilus ) could be transferred to a completely different species— E. coli —and it would work there. This was important because it demonstrated the universality of the system.flagshippioneering

2006-2011: Developing the Foundation

In the following years, scientists around the world began to study CRISPR in more detail. Fiona Barrangou and others demonstrated exactly how CRISPR works—how bacteria “learn” to recognize viruses and use this knowledge to protect themselves.nature

Several variants of CRISPR systems have been discovered – CRISPR-Cas9 , CRISPR-Cas12a , and others. Each system had its own Cas proteins – enzymes that perform the actual “cutting” of DNA.pmc.ncbi.nlm.nih

It turned out that Cas9 , from Streptococcus pyogenes (the bacterium that causes angina), was particularly remarkable. When prompted by guide RNA, it would precisely cut DNA exactly where instructed.pmc.ncbi.nlm.nih

By 2011, scientists knew almost everything they needed to know about CRISPR in nature. But no one had yet considered: what if, instead of letting bacteria do what they do naturally, we scientists taught Cas9 to do what we wanted?

The San Juan Meeting and the History That Was Written

In 2011, at a scientific conference in San Juan, Puerto Rico, two scientists from different sides of the Atlantic met by chance.pmc.ncbi.nlm.nih

Jennifer Doudna , a protein structuralist at the University of California, Berkeley, specialized in studying biological mechanisms at the molecular level. Emmanuelle Charpentier , a microbiologist at Umeå University in Sweden, also studied bacterial immune systems.innovativegenomics+1

They talked about CRISPR. Doudna was fascinated; Charpentier was an expert. They decided to collaborate.pmc.ncbi.nlm.nih

2011: Charpentier Discovers the Third Missing Piece

Before Doudna and Charpentier deepened their collaboration, Charpentier had made a significant discovery in her Umeå lab. She was studying CRISPR with Streptococcus pyogenes and discovered something that would change everything.mpg

It turned out that in addition to krRNA (CRISPR RNA) and Cas9, there was a third, critically important component: tracrRNA (trans-activating crRNA) . This was a small but crucial RNA molecule.pmc.ncbi.nlm.nih+1

This was a groundbreaking observation because the tracrRNA turned out to be a “bridge”—it connected Cas9 to the krRNA in such a way that Cas9 knew where to look and where to cut.pmc.ncbi.nlm.nih

2012: The Turning Point When Nature Became a Tool

Now Doudna and Charpentier had all the pieces of the puzzle. In their UC Berkeley/Umeå lab, they worked together (communicating across the ocean) to assemble CRISPR-Cas9 into something that could be a controllable tool.embryo.asu

Their key contribution was elegant: instead of using two separate RNA molecules (krRNA and tracrRNA), they combined them into a single molecule , which they called single guide RNA (sgRNA) .embryo.asu

Why was this important? Because it simplified the technology. Instead of programming two different RNAs, scientists now had to program just one. It was like going from using a computer with two buttons to one with a single large button labeled with what you wanted to do.mpg+1

Experiment: Testing in Dish

In their experiment, Doudna, Charpentier and their team (including Martin Jinek and Michael Hauer from Berkeley, and Krzysztof Chylinski and Ines Fonfara from Umeå) set up a laboratory scene:embryo.asu

  1. They produced pure Cas9 protein – an enzyme not yet “programmed”embryo.asu
  2. They created guide RNA that could program Cas9 to search for a specific DNA sequence.embryo.asu
  3. They combined them in a laboratory tube – along with the target DNAembryo.asu

And they waited.

What happened: Cas9 precisely cut the DNA exactly where the guide RNA told it to . Not just anywhere—right there.embryo.asu

But that wasn’t the goal. Doudna and Charpentier were pursuing something much bigger: demonstrating that the CRISPR-Cas9 system can be programmed like a hyper-precise tool that scientists can target to ANY DNA sequence .embryo.asu

When Doudna and Charpentier showed they could program five different guide RNAs, each targeting a different site in the DNA, the idea was clear: It could work for any sequence a scientist wanted to edit .embryo.asu

Science Publication: The Moment When Everything Changed

Their manuscript reached the editorial office of Science in 2012.pmc.ncbi.nlm.nih

In the June 2013 issue of Science , an article was published: “RNA-guided genetic engineering of human pluripotent stem cells.” The title didn’t sound revolutionary, but its content was incredible.pmc.ncbi.nlm.nih

The article included a detailed description of the three CRISPR-Cas9 components:pmc.ncbi.nlm.nih

  • Cas9 protein (enzyme)
  • crRNA (lead part)
  • tracrRNA (connector)

And importantly , they showed how all three could work together as a programmed, precise DNA editing tool .pmc.ncbi.nlm.nih

But that was only part of it. Doudna and Charpentier proposed something radical: What if scientists could use this system not only in bacteria, but also in eukaryotic cells—like human cells?pmc.ncbi.nlm.nih

The scientific world reacted with madness.

The Year After: Feng Zhang and the First Editions in Mammalian Cells

In 2013, just a few months after Doudna-Charpentier’s publication, Feng Zhang of the MIT Broad Institute published his own paper in Science .embryo.asu

Zhang took the CRISPR-Cas9 described by Doudna and Charpentier and demonstrated that it could be delivered into living mouse and human cells and edit their genome .embryo.asu

It was a massively important demonstration. Theoretically, it worked in a tube. But would it work in living cells? Yes, and Zhang is proof.embryo.asu

Now scientists had not only a conceptual tool, but a practical tool.

Revolution: Six Months, Thousands of Articles

Six months after Doudna-Charpentier’s publication, dozens of labs around the world had already begun experimenting with CRISPR-Cas9.news.berkeley

Here’s why CRISPR was so transformative compared to previous technologies (such as ZFNs – Zinc Finger Nucleases, and TALENs – Transcription Activator-Like Effector Nucleases):ijisrt

aspectZFNLANGUAGESCRISPR-Cas9
Ease of designVery difficult, requires protein engineeringDifficult, but easier than ZFNVery easy – just change the RNA
Time to actWeeks/monthsDays/weeksHours/days
CostDearEasyVery cheap
PrecisionHighHighHigh
VersatilityLimited to certain sequencesMore universalUniversal
Multiplex (multiple targets at once)DifficultDifficultEasy

Scientists could now take any DNA sequence – from a human gene, mitochondrial DNA, bacteria, plants – and program Cas9 to cut it in hours.news.berkeley

It was like going from handwriting every letter of a document to having a golden pen that could write whatever you wanted.

First Triumphs: 2013-2015

By 2015, CRISPR-Cas9 had already been used to:

  • Gene editing in mouse cells – creating disease modelsaddgene
  • Mutation Repair – Scientists Worked on Serum Fibrosis and Beta-Thaliasiaaddgene
  • Gene function research – blocking genes to see what they doaddgene
  • Plant resistance formations – plants resistant to drought or diseaseaddgene

In 2015, Science named CRISPR its “Breakthrough of the Year” – the only laboratory tool to win this prestigious award.bitesizebio

Parallel History: The Battle for Patents

While Doudna and Charpentier published their results in Science , almost simultaneously, Zhang at MIT/Broad Institute was also working on the CRISPR project. The result: a patent controversy exists today.insights

Doudna and Charpentier filed their patent application in March 2013, but with priority from May 2012.insights

Zhang submitted his application in October 2013, but with priority from December 2012.insights

Zhang received the first patent – ​​the U.S. Patent and Trademark Office granted him Patent No. 8,697,359 in April 2015. But Doudna and Charpentier also hold patents (European and other).broadinstitute+1

In the world of medicine and business – where patents mean money – this battle continues to this day.

A Dramatic Turning: The Nobel Prize in 2020

In a year when the world was grappling with COVID-19, the Swedish Academy of Sciences awarded the 2020 Nobel Prize in Chemistry to exactly two women: Emmanuelle Charpentier and Jennifer Doudna “for developing a method for genome editing.”Nobel Prize

This was historic. It was the first time the Nobel Prize in Chemistry was awarded solely to two women . Charpentier and Doudna were pioneers not only in science but also in gender equality in science.pmc.ncbi.nlm.nih

During her Nobel speech, Doudna expressed her gratitude to Charpentier: “Without her commitment and vision, this would not have been possible.”

From 2013 to 2025: How Far We’ve Come

Fast forward to today. Since the first Science article in 2012, CRISPR has gone from a laboratory curiosity to a real-world tool in medicine:

  • 2019 : First CRISPR clinical trial in sickle cell patients in the USpmc.ncbi.nlm.nih
  • 2023 : FDA approves the first CRISPR-Cas9-based drug for sickle cell disease and thalassemia – Casgevypmc.ncbi.nlm.nih
  • 2024 : More than 1,500 CRISPR clinical trials worldwideinnovationhub
  • 2025 : CRISPR-edited cells are now being delivered to patients who say they “feel like new people”innovationhub

Summary: How Bacteria Taught Us to Heal

The story of CRISPR is a story of discovery that began with curiosity—why do bacteria have these strange DNA repeats?—and led to a medical revolution.

From Yoshizumi Ishino in 1987 discovering the mysterious sequences, to Francisco Mojica understanding their function, to Jennifer Doudna and Emmanuelle Charpentier seeing that the bacterial immune system could be a tool for humanity – each step has been extraordinary.mdpi+4

What bacteria have developed over millions of years of evolution—a self-defense system against viruses—has taught us how to treat human genetic diseases. Nature is our best engineer. We just had to pay attention.pmc.ncbi.nlm.nih+1

Today, in 2025, CRISPR is beyond the “can work” stage and entering the “actually works in patients” stage. This journey from infectious discovery to reliable medical tool took 38 years. But the wait was worth it.


Sources and References

– MDPI: CRISPR-Cas: Converting A Bacterial Defence Mechanism into A State-of-the-Art Genetic Manipulation Tool (2019)mdpi
– PMC/NIH: CRISPR-Cas9: From a bacterial immune system to genome-edited human cells in clinical trials (2017)pmc.ncbi.nlm.nih
– BioCompare: The History and Evolution of CRISPR (2021)biocompare
– Lab Biotechnology EU: Francis Mojica, the Spanish Scientist Who Discovered CRISPR (2022)labiotech
– Bitwise Bio: A Brief History of CRISPR-Cas9 Genome-Editing Tools (2024)bitesizebio
Wikipedia: Francisco Mojicawikipedia
– Innovative Genomics Institute: Jennifer Doudna and Emmanuelle Charpentier – Behind the Development of CRISPR (2025)innovativegenomics
– Flagship Pioneering: A History of CRISPR (2020)flagshippioneering
– PMC/NIH: Nobel Prize 2020 in Chemistry honors CRISPR (2020)pmc.ncbi.nlm.nih
– PMC/NIH: Breaker of chains (2021)pmc.ncbi.nlm.nih
– ASU Embryo Project: Jennifer Doudna and Emmanuelle Charpentier’s Experiment (2017)embryo.asu
– Broad Institute: Statements and background on CRISPR patent process (2025)broadinstitute
– CRISPR Therapeutics: Dr. Emmanuelle Charpentiercrisprtx
– Insights.bio: Revolutionizing genome editing with CRISPR/Cas9: patent dispute (2015)insights
– Max Planck Institute: Emmanuelle Charpentier: An artist in gene editing (2017)mpg
– Nobel Prize Official: Jennifer A. Doudna (2018)Nobel Prize
– PMC/NIH: The genome-editing decade (2021)pmc.ncbi.nlm.nih
– PMC/NIH: Blossom of CRISPR technologies and applications (2018)pmc.ncbi.nlm.nih
– International Journal of Innovation and Scientific Research: Comparative Review of ZFN, TALEN, and CRISPR/Cas9ijisrt
– UC Berkeley News: How CRISPR worksnews.berkeley
– AddGene: CRISPR History and Development for Genome Engineering (2024)addgene
– Innovation Hub: The Breakthrough of CRISPR (2023ub: The Breakthrough of CRISPR (2023)pmc.ncbi.nlm.nih

  1. https://www.labiotech.eu/interview/francis-mojica-crispr-interview/
  2. https://en.wikipedia.org/wiki/Francisco_Mojica
  3. https://bitesizebio.com/47927/history-crispr/
  4. https://www.biocompare.com/Editorial-Articles/578958-The-History-and-Evolution-of-CRISPR/
  5. https://www.flagshippioneering.com/timelines/a-history-of-crispr
  6. https://pmc.ncbi.nlm.nih.gov/articles/PMC8042634/
  7. https://pmc.ncbi.nlm.nih.gov/articles/PMC6199817/
  8. https://www.nature.com/articles/s41467-018-04252-2
  9. https://innovativegenomics.org/news/jennifer-doudna-emmanuelle-charpentier-development-crispr-genome-editing/
  10. https://crisprtx.com/about-us/leadership/dr-emmanuelle-charpentier
  11. https://www.mpg.de/10729312/emmanuelle-charpentier
  12. https://pmc.ncbi.nlm.nih.gov/articles/PMC7782372/
  13. https://embryo.asu.edu/pages/jennifer-doudna-and-emmanuelle-charpentiers-experiment-about-crisprcas-9-systems-role-adaptive
  14. https://news.berkeley.edu/2017/02/15/how-crispr-works-and-what-it-can-do/
  15. https://www.ijisrt.com/assets/upload/files/IJISRT25APR2221.pdf
  16. https://www.addgene.org/crispr/history/
  17. https://www.insights.bio/cell-and-gene-therapy-insights/journal/article/535/Revolutionizing-genome-editing-with-CRISPR-Cas9-patent-battles-and-human-embryos
  18. https://www.broadinstitute.org/crispr/journalists-statement-and-background-crispr-patent-process
  19. https://www.nobelprize.org/prizes/chemistry/2020/doudna/facts/
  20. https://pmc.ncbi.nlm.nih.gov/articles/PMC8571477/
  21. https://www.innovationhub.world/post/the-breakthrough-of-crispr
  22. https://www.mdpi.com/2079-6382/8/1/18/pdf
  23. https://pmc.ncbi.nlm.nih.gov/articles/PMC5470512/
  24. https://pmc.ncbi.nlm.nih.gov/articles/PMC4491743/
  25. https://pmc.ncbi.nlm.nih.gov/articles/PMC4084950/
  26. https://academic.oup.com/ismej/advance-article-pdf/doi/10.1093/ismejo/wrae108/58280201/wrae108.pdf
  27. https://pmc.ncbi.nlm.nih.gov/articles/PMC3883426/
  28. https://pmc.ncbi.nlm.nih.gov/articles/PMC5847661/
  29. https://pmc.ncbi.nlm.nih.gov/articles/PMC11285788/
  30. https://gna.it.com/crispr-discovery-history-pioneers
  31. https://breakthroughprize.org/Laureates/2/L63
  32. https://en.wikipedia.org/wiki/CRISPR
  33. https://www.bioagilytix.com/blog/origins-of-crispr-how-it-came-to-be/
  34. https://elifesciences.org/articles/73601
  35. https://pmc.ncbi.nlm.nih.gov/articles/PMC10541141/
  36. https://pmc.ncbi.nlm.nih.gov/articles/PMC5239572/
  37. https://pmc.ncbi.nlm.nih.gov/articles/PMC9377665/
  38. https://pmc.ncbi.nlm.nih.gov/articles/PMC5214730/
  39. https://pmc.ncbi.nlm.nih.gov/articles/PMC6014596/
  40. https://en.wikipedia.org/wiki/Feng_Zhang
  41. https://en.wikipedia.org/wiki/Emmanuelle_Charpentier
  42. https://pmc.ncbi.nlm.nih.gov/articles/PMC10454384/
  43. https://pmc.ncbi.nlm.nih.gov/articles/PMC10373057/
  44. https://pmc.ncbi.nlm.nih.gov/articles/PMC9589773/
  45. https://pmc.ncbi.nlm.nih.gov/articles/PMC6800964/
  46. https://pmc.ncbi.nlm.nih.gov/articles/PMC5319590/
  47. https://pmc.ncbi.nlm.nih.gov/articles/PMC4191047/
  48. https://www.sciencedirect.com/science/article/abs/pii/S0966842X16300683
  49. https://www.ptglab.com/news/blog/crispr-cas9-talens-and-zfns-the-battle-in-gene-editing/

The last step towards HIV cure – EBT-101 protein

EBT-101: Are we on the verge of finding a cure for HIV?

HIV, or human immunodeficiency virus, has shaped modern medicine and transformed the lives of countless people since its discovery in the early 1980s. Today, thanks to advances in antiretroviral medicine (ART), people with HIV can live long and healthy lives. However, even with daily medication, the virus lurks—like a cat in the shadows—ready to strike the moment we stop taking it.

What if we could banish the virus from hiding…for good? Meet EBT-101 , a novel gene-editing treatment that aims to cure HIV, not just control it. Sounds like science fiction? Scientists are testing it right now. Let’s take a closer look and learn more about this potential medical revolution.


Why is HIV so difficult to cure?

HIV is insidious. It not only circulates in the blood but also penetrates the DNA of immune cells, creating hidden “reservoirs.” As long as you take your medication daily, the virus remains inactive. But interrupt it for a moment, and HIV quickly reactivates.

That’s why it’s so hard to find a real cure for HIV: the virus is part of you, hidden, almost like a computer virus buried in your hard drive.


What makes the EBT-101 course unique?

EBT-101 is based on the wonder tool of modern genetics: CRISPR-Cas9 . Imagine super-precise scissors that can locate and cut the specific DNA fragments where HIV hides.

But EBT-101 isn’t just about CRISPR therapy! Here’s what makes it so interesting:

  • Multiplex gene editing  : Most gene editing targets only one site. EBT-101 targets three places where HIV can hide in DNA. It’s like a triple-locked door—and three keys to ensure nothing escapes!
  • Long-term effects  : Animal studies indicate that a single dose of therapy can eliminate enough of the virus to permanently inactivate it.
  • AAV delivery  : The tool is introduced into the body using a harmless helper virus, known as  an adeno-associated virus (AAV)  , which sends gene-editing instructions directly to cells.

How do clinical trials work?

First step: safety first

Phase 1 clinical trials for EBT-101 began in 2022, meaning real people are already participating in the studies ( https://www.clinicaltrials.gov/study/NCT05144386 ). At this early clinical stage, the main questions are:

  • Is the treatment safe?
  • Does it cause any unexpected or dangerous side effects?
  • Can scientists test whether removing HIV from cells is effective?

Who can participate?

The first study involves HIV-1-infected adults whose viral load remained very stable for years on treatment. This is important because researchers need a clear, stable starting point to see if EBT-101 actually has an effect.

What will happen next?

If the study shows that EBT-101 is safe (does not cause serious side effects or “off-target” genetic modifications), the next steps will be to try to answer the following questions:

  • How well does the body cleanse itself of hidden HIV viruses?
  • Can you safely stop taking HIV medications without risking a viral relapse?
  • How long do the effects last?

Answering these questions will take several years and further studies in larger groups. A scientific breakthrough would be to discover that a single therapy proved effective in just a handful of people.


What are the biggest challenges for EBT-101?

Let’s be curious and honest—eliminating HIV isn’t as easy as cutting toast! Here are some of the serious challenges we face:

1. Completely reach all HIV reservoirs

HIV hides in many types of immune system cells, in various tissues—deep lymph nodes, the intestines, the brain. Therapy must find each infected cell to prevent the virus from spreading again. This “needle in a haystack” problem is one of the most difficult challenges in HIV research.

2. Avoiding side effects

CRISPR is very precise, but not perfect. If the gene-editing scissors make a mistake—cutting healthy human DNA instead of the virus itself—it could cause serious health risks, such as the development of cancer or other diseases. Clinical trials are closely monitored for these risks.

3. The body’s immune response

Introducing CRISPR tools and a carrier virus (even a harmless one like AAV) can attract the attention of the body’s defense mechanisms. If the immune system attacks the carrier system, the therapy may be less effective or trigger inflammation.

4. Durability: Is one dose enough?

Early research offers hope, but we don’t yet know whether a single treatment eliminates HIV for life or if the virus can return years later. Researchers will need to follow participants long-term to be sure.

5. Availability and cost

New, complex gene therapies are typically very expensive initially and may be limited to wealthy countries or well-funded research centers. Ensuring EBT-101 is available to all people living with HIV will be a major challenge in the future.

6. Ethical and Regulatory Obstacles

Because it involves editing the genome of human cells, strict ethical rules and debates apply. Long-term effects must be understood before widespread use is considered.


Where are we now and what awaits us?

Scientists around the world are eagerly watching the EBT-101 trials. If successful, they could pave the way not only to a cure for HIV but also for other diseases caused by viruses hidden in our DNA. Companies and universities are racing to improve gene-editing tools, reach more cells, and make the therapy safer and easier to administer.

EBT-101 is not yet a cure, but the idea of ​​curing HIV, rather than controlling the disease, could become a reality in our lifetime.


Summary: Hope on the Horizon

EBT-101 is one of the boldest ideas in modern medicine. Using CRISPR gene editing, it aims to find and remove the hidden HIV virus from human DNA, offering hope for a true, lasting cure. The path from the laboratory to the patient’s bedside is long, fraught with scientific puzzles and ethical questions, but each step brings us closer to a world where HIV no longer lurks in the shadows.

Could people with HIV really close this chapter of their lives forever? If so, EBT-101 could go down in history as a true medical miracle.

CRISPR–Cas9 protein

The story starts since CRISPR–Cas9 discovery. Noticed and appreciated  by Emmanuelle Charpentier. After spending years working on Streptococcus pneumoniae bacteria defense mechanisms against antibiotics. She discovered an RNA that controls the synthesis of a class of molecules that are important in pro-life and self-defense processes. The though she spotted on was a patterned stretch of DNA called CRISPR in the genome of some bacteria, where it serves as part of a defense system against viruses. By copying part of an invading virus’ DNA and inserting it into that stretch, bacteria are able to recognize the virus if it invades again, and attack it by cutting its DNA. Different CRISPR systems have different ways of organizing that attack; all of the systems known at the time involved an RNA molecule called CRISPR RNA. Using bioinformatics in collaboration with Jörg Vogel they’ve noticed a dependency between used programmed sequence RNA and result on the genome. That showed up 3 main elements of this method tracrRNA, CRISPR RNA and the Cas9 protein which was noticed in 2005 by lexander Bolotin, French National Institute for Agricultural Research (INRA). But the first scientist that totticed CRISPR was . Also the coded part of the RNA (crRNA) was traced by John van der Oost from Netherlands this time using E-scherichia coli bacteria. The next breakthrough was made in 2008 by Marraffini and Sontheimer from USA. They evidenced that using CRISPR technique  works not as RNA suppressor but in fact targets DNA. The next discovery belonged again to Emmanuelle Charpentier. She noticed tracrRNA forms a duplex with crRNA, and that it is this duplex that guides Cas9 to its targets.  In thge summer of 2009 together with Elitza Deltcheva made and successful experiment of editing DNA. Another step was achieved in 2011 by Virginijus Siksnys from Lithuania. The team “transplanted” CRISPR into the bacteria which does not contain a Type II system – E. coli. The experiment wass succesful – the CRISPR unit turned out to be autonomous. They also successfully made experiments with programmed crRNA part. But the real use was done by Feng Zhang from Broad Institute of MIT that have demonstrated targeted genome erase in human and mouse cells.

Source :

http://www.nature.comhttp://feldan.comhttps://www.broadinstitute.org